Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.91 (market cap $39.15B), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TTWO | ZBH | |
|---|---|---|
Market Cap | $39.15B | $16.95B |
Volume | 2,708,429 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $262.29 | $103.98 |
52-Week Low | $189.69 | $79.58 |
Typical Hold Time | 111 Days | 89 Days |
Enterprise Value | $40.27B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $213.88, up 4.84% with bullish technical signals and strong analyst support. The company shows mixed fundamentals with revenue growth to $5.63B but negative net income of -$4.48B, though recent earnings beats and the upcoming GTA VI launch provide optimism. Technical indicators show the stock trading near resistance at $215 with RSI suggesting potential overbought conditions.
The outlook remains positive driven by GTA VI's November launch, with analysts projecting 37% upside to $292.30 consensus target. Key risks include persistent profitability challenges, high debt levels, and execution pressure on major game releases. Institutional ownership trends show continued confidence despite recent financial headwinds.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
